Latest News
NeuroSense concludes equity offering program; Fully funded beyond ALS Phase 2b results
2 October 2023 - Biotechnology company NeuroSense Therapeutics Ltd (Nasdaq: NRSN) declared on Monday that it has decided to end its 'at-the-market' (ATM) equity offering program, effective 4 October 2023.The company, focused on treatments f...
SAB Biotherapeutics secures up to USD130m in private placement to advance type 1 diabetes drug
2 October 2023 - Clinical-stage biopharmaceutical company SAB Biotherapeutics (Nasdaq:SABS) announced on Monday a private placement agreement with accredited investors, raising up to USD130m in gross proceeds.This funding will propel the development ...
Acurx Pharmaceuticals announces successful early end to Phase 2b trial for ibezapolstat in C. difficile infection Treatment
2 October 2023 - Clinical stage biopharmaceutical company Acurx Pharmaceuticals Inc (NASDAQ:ACXP) announced on Monday the early discontinuation of the Phase 2b clinical trial for its lead antibiotic candidate, ibezapolstat, targeting Clostridioides d...
Rocket Pharmaceuticals granted FDA Priority Review for RP-L201 gene therapy in severe LAD-I
2 October 2023 - Biotechnology company Rocket Pharmaceuticals Inc (NASDAQ:RCKT) said on Monday that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review for RP-L201 (marnetegragene...
Holmusk and Veradigm expand strategic collaboration to advance behavioral health innovation
2 October 2023 - Healthcare data and technology solutions provider Veradigm Inc (NASDAQ: MDRX) and Holmusk, a global leader in behavioral health real-world evidence, on Monday announced a new phase in a strategic collaboration. This development invol...